



Artificial Intelligence for Predicting Type 2 Diabetes and MASLD Risk in Children with Obesity

Frank Preaubert*

Department of Pediatric Metabolic Medicine, University of Sao Paulo, Sao Paulo, Brazil

DESCRIPTION

Childhood obesity has become an important metabolic health challenge because excessive adiposity during early life can contribute to abnormalities in glucose regulation, lipid metabolism, liver function and cardiovascular health. Two important complications associated with metabolic dysfunction are Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Identifying children who are more likely to develop these conditions before substantial organ damage occurs could support earlier clinical attention and individualized prevention. Artificial Intelligence (AI) provides an emerging approach for integrating multiple clinical and biological variables into predictive models capable of estimating individual risk. Traditional assessment of metabolic risk generally considers variables such as body mass index, waist circumference, blood pressure, fasting glucose, lipid concentrations, family history, physical activity and dietary patterns. Although these measures remain valuable, their interpretation can become challenging when many interacting factors influence an individual's future risk.

AI-based models can process large numbers of variables simultaneously and identify complex relationships that may not be apparent through conventional statistical approaches. This capability makes AI particularly relevant to pediatric obesity, where metabolic trajectories can differ substantially between children with similar body weight. A predictive model for T2DM could incorporate demographic characteristics, growth patterns, adiposity measures, glucose-related biomarkers, lipid profiles, blood pressure, family history and indicators of insulin resistance. Longitudinal information may be especially valuable because metabolic risk is not determined by a single measurement. Changes in body composition, glucose concentrations and other metabolic indicators over time can provide information about an evolving risk trajectory. Machine-

learning algorithms can evaluate these patterns and generate individualized probability estimates rather than relying exclusively on predefined clinical thresholds.

MASLD presents another important target for predictive modelling. The condition involves accumulation of fat in the liver in association with metabolic dysfunction and can progress in some individuals toward inflammation, fibrosis and more advanced liver disease. Children with obesity may have increased susceptibility, but risk is not uniform. An AI model could potentially combine anthropometric measurements, liver-associated biochemical markers, metabolic characteristics, age, sex and other clinical information to identify children who warrant closer evaluation. Such a model would not replace diagnostic procedures but could assist clinicians in prioritizing assessment. One advantage of AI is its ability to recognize nonlinear relationships. For example, the relationship between adiposity and metabolic risk may vary according to age, pubertal development, sex, genetic background and metabolic characteristics. A machine-learning system can account for interactions among these variables when sufficient high-quality data are available. Models can also be designed to accommodate missing information and different forms of clinical data, although such capabilities require careful validation to prevent inaccurate predictions.

The quality of an AI prediction system depends strongly on the data used to develop it. Pediatric populations are biologically diverse and datasets drawn from a single hospital or geographic region may not represent children from other backgrounds. Differences in nutrition, healthcare access, ancestry, socioeconomic circumstances and diagnostic practices can influence model performance. External validation across diverse pediatric populations is therefore essential before an algorithm is incorporated into routine clinical decision-making. Interpretability is another important consideration. A prediction indicating that a child has elevated risk should ideally provide

Correspondence to: Frank Preaubert, Department of Pediatric Metabolic Medicine, University of Sao Paulo, Sao Paulo, Brazil, Email: frank.preaubert@pediatrics.usp.br

Received: 30-Aug-2025, Manuscript No. JDMGP-25-32409; **Editor assigned:** 02-Sep-2025, PreQC No. JDMGP-25-32409; **Reviewed:** 16-Sep-2025, QC No. JDMGP-25-32409; **Revised:** 22-Sep-2025, Manuscript No. JDMGP-25-32409; **Published:** 30-Sep-2025, DOI: 10.35248/2153-0602.25.16.396

Citation: Preaubert F (2025). Artificial Intelligence for Predicting Type 2 Diabetes and MASLD Risk in Children with Obesity. J Data Mining Genomics Proteomics. 16:396.

Copyright: © 2025 Preaubert F. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

clinicians with understandable information about the factors contributing to that estimate. Transparent models can make it easier to identify potentially modifiable influences, such as changes in physical activity, nutrition, sleep or excessive weight gain. Explainable AI methods may help clinicians understand how individual variables contribute to predictions while maintaining the advantages of computational modelling.

Privacy and responsible data management are equally important when working with children's health information. Pediatric datasets can contain sensitive clinical and demographic information, requiring appropriate safeguards for collection,

storage, processing and sharing. Algorithms should also be evaluated for unintended bias because systematic differences in training data can produce unequal performance among population groups. Responsible implementation requires technical accuracy as well as attention to fairness, privacy and clinical accountability. AI should be regarded as a decision-support technology rather than an autonomous replacement for pediatric healthcare professionals. A high-risk prediction does not mean that a child will inevitably develop T2DM or MASLD, while a low-risk prediction cannot guarantee future metabolic health.